Human neuropeptide Y (hNPY) is one of the most widely expressed neurotransmitters in the human central and peripheral nervous systems. It consists of 36 highly conserved amino acid residues, and was first isolated from the porcine hypothalamus in 1982. While it is the most recently discovered member of the pancreatic polypeptide family (which includes neuropeptide Y, gut-derived hormone peptide YY, and pancreatic polypeptide), NPY is the most abundant peptide found in the mammalian brain. In order to exert particular functions, NPY needs to bind to the NPY receptor to activate specific signaling pathways. NPY receptors belong to the class A or rhodopsin-like G-protein coupled receptor (GPCR) family and signal via cell-surface receptors. By binding to GPCRs, NPY plays a crucial role in various biological processes, including cortical excitability, stress response, food intake, circadian rhythms, and cardiovascular function. Abnormal regulation of NPY is involved in the development of a wide range of diseases, including obesity, hypertension, atherosclerosis, epilepsy, metabolic disorders, and many cancers. Thus far, five receptors have been cloned from mammals (Y1, Y2, Y4, Y5, and y6), but only four of these (hY1, hY2, hY4, and hY5) are functional in humans. In this review, we summarize the structural characteristics of human NPY receptors and their role in metabolic diseases.
Introduction
Neuropeptide Y is widely expressed in the human central and peripheral nervous system. This is a highly conserved 36-amino acid peptide which was first isolated from porcine hypothalamus in 1982 [1] . There are three members of the pancreatic polypeptide family,
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GPCR/AC-inhibiting GPCR/cell surface receptor/ neuropeptide signaling pathways locomotory behavior regulation of multicellular organism growth/blood pressure outflow tract morphogenesis blood circulation feeding behavior glucose metabolic process sensory perception of pain GPCR/cell surface receptor /ACinhibiting GPCR/dopamine secretion/ neuropeptide signaling pathways positive regulation of cytosolic calcium ion concentration/peptide secretion and circadian sleep/wake cycle, non-REM sleep/ smooth muscle contraction/ cell-substrate adhesion negative regulation of neurological system process/synaptic transmission/excitatory postsynaptic potential/ secretion/ feeding behavior/cAMP biosynthetic process/synaptic transmission, glutamatergic sensory perception of pain locomotory/feeding behavior outflow tract morphogenesis cardiac left ventricle morphogenesis behavioral fear response nitric oxide mediated signal transduction aging chemical synaptic transmission GPCR/cell surface receptor/neuropeptide signaling pathways blood circulation feeding behavior digestion GPCR/cell surface receptor/ neuropeptide signaling pathway positive regulation of acute inflammatory response/cell and smooth muscle proliferation/ERK1 and ERK2 cascade negative regulation of glutamate secretion/apoptotic process/synaptic transmission, GABAergic/acute inflammatory response to antigenic stimulus generation of ovulation cycle rhythm eating/feeding behavior outflow tract morphogenesis aging cardiac left ventricle morphogenesis chemical synaptic transmission namely the neuropeptide Y, the gut-derived hormone peptide YY (PYY) and pancreatic polypeptide (PP). Endogenous ligands (usually NPY, PYY and PP) and their C-terminal segments, especially those with parent residues 3-36 and 13-36 [2, 3] activate Y receptors via binding and triggering a conformational change of the Y receptors (Table 1) . NPY receptors are monomer proteins and belong to the class A or rhodopsin-like G-protein coupled receptors (GPCRs) [4] . After binding to the ligands, the Gi or G 0 subunit of the heterotrimeric G protein complex is released and in turn leads to the inhibition of adenylate cyclase, which prevents the conversion of ATP to the second signaling molecule, cAMP [4] . Finally, cAMP levels are reduced and the Ca 2+ and K + channels are modulated [5] . Generally, NPY receptors are coupled to the Gi or G 0 subunit. In rabbit smooth muscle cells, it has also been reported that Y2 and Y4 receptors could bind to the Gq protein and promote the production of inositol 1, 4,5-triphosphate (IP3) by activating phospholipase C-β (PLC) [6] . In rat arcuate neurons, it was reported that NPY receptors could regulate K + and Ca 2+ channels, and G protein-coupled inwardly rectifying potassium channels ( Fig. 1) [4] . In addition to the seven membrane-confined he-lices, the heptahelical GPCRs have four extracellular and four intracellular segments, which could be labeled as ec1-ec4 and ic1-ic4, respectively. The ec1 is an extracellular N-terminus and the ic4 is a intracellular C-terminus which cloud anchor onto the membrane by palmitoylation. The other six segments form three extracellular loops I-III and intracellular loops I-III was formed by the ec2-ec4 and ic1-ic3 segments, respectively. In extracellular regions, a disulfide bond between ec2 and ec3 segments is formed by two highly conserved cysteine (Cys) residues. This disulfide bond is a general feature of class A GPCRs and has been related to the stability of these receptors [7, 8] . The extracellular parts of the receptor can also be modified by glycosylation. In the intracellular regions, the C terminal tail, namely the ic4 segment, and the ic2 segment form two G protein binding sites. These two helices interact with signal transduction protein GTPases and bind to G proteins which consequently form an elementary complex coupled to Y receptors [9] .
Thus far, seven different Y receptors (Y1-Y8) have been reported in vertebrates [10] [11] [12] [13] [14] , of which five (Y1, Y2, Y4, Y5, and y6) are cloned from mammals and four (hY1, hY2, hY4 and hY5) are proven functional in humans [15] . According to contemporary sequence alignment (current UniProtein sequences aligned in clustalO program), the Y receptors could be classified into two families, the Y1-Y4-Y6-Y8 (Y5) and the Y2-Y7 families; the first family is strongly expressed in neural tissue, and the second in visceral organs, especially kidney and intestine. In humans，the Y5 receptor is slightly better aligned with the Y1 (23%) than with the Y2 (22%); Y1 and Y2 align at 29%, Y1 and Y4 at 51%, Y4 and Y5 at 24%. The Y2 receptor is akin to neurokinin /tachykinin GPCRs, both orexin receptors, two galanin receptors and three somatostatin receptors [16] , and could be phylogenetically more recent than the Y1 receptor. Fig. 1 . The molecular mechanisms and signaling pathways of GPCRs. In a resting state, the three subunits of GPCRs are complexed and bound to GDP. GPCRs change conformation and undergo activation by binding to special ligands, and can then function as a guanine nucleotide exchange factor (GEF). Once activated, the Gβγ complex (formed by close binding between the β and γ subunits) is released from the Gα subunit and exchanges bound GDP for GTP. Then, the Gα subunit, and the bound GTP, separates from the Gβγ complex and acts as an intracellular signaling molecule, or target protein, hinging on the top of its α subunit (Gαs, Gαi/o, Gαq/11, Gα12/13). The free Gβγ complex can function as a messenger molecule by interacting with ion gating channels, or other types of transducer, such as cAMP. Generally, there are two essential signaling pathways involving the GPCRs: the cAMP signaling pathway and the phosphatidylinositol signaling pathway.
Fig 1
In the human central and peripheral nervous system, neuropeptide Y receptors are encoded by different genes and show distinct tissue distributions, as well as intracellular signaling pathways; this suggests that they function in a variety of physiological processes. Different Y receptors mediate different processes and diseases such as food intake [17] , obesity, hypertension, atherosclerosis, epilepsy, metabolic disorders, fracture healing [18] and many cancers [19] [20] [21] [22] [23] [24] [25] [26] . By binding to different receptors，NPY plays various roles in human biological processes, and sometimes can even function quite differently. For instance, it has been reported that the down regulation of hY1 receptors and hY5 receptors can reduce feeding effect, whereas the increased expression of hY2 receptors and hY4 receptors can exert anorexigenic effects [27] . Selectively stimulating or blocking the differentially acting Y receptors has demonstrated clear therapeutic potential in treating obesity and metabolic disorders [28, 29] . For example, the administration of NPY in the rat central nervous system induces hyperphagia, as well as a reduction in energy expenditure and the activation of lipogenic enzymes in the liver and adipose tissues, processes which are closely associated with obesity and metabolic disorders [16] . Herein, we summarize the structural characteristics of human NPY receptors (hY1, hY2, hY4 and hY5) and their relationships with metabolic diseases.
The characteristics of human NPY receptors
Over recent years, there has been much research carried out on the genes encoding NPY receptors, particularly using a variety of gene-targeting techniques. Many of these investigations have involved the generation of NPY knockout mice; the deletion of genes encoding NPY receptors was used to determine their roles in physiological functions such as energy metabolism and the regulation of food intake.
Neuropeptide Y receptor Y1
The human Y1(hY1) receptor was first discovered and cloned by Herzog et al. [30] by analyzing and characterizing a number of peptide fragments. The Y1 receptor is composed of 384 amino acids and its native agonists are NPY and PYY. The Y1 receptor can be activated by NPY in an endogenous and non-subtype selective way (Table 1 ) and shares over 92% sequence identity with that of its orthologues such as mouse, rat, pig, guinea pig, and cow. Generally, the homologies among human Y receptor subtypes are very low. The hY1 and hY4 receptors share the highest sequence similarities which are thought of as belongings to the same gene family, while hY2 and hY5 each belongs to an autonomous one [13] . In situ hybridization and immunohistochemistry have been used to reveal the distribution of the Y1 receptor and its binding sites. The Y1 receptor was predominantly expressed in the periphery, hypothalamus, hippocampus, neocortex and thalamus (Table 1 ). In rats, Y1 receptor mRNA expression was detected in pancreatic β cells [31] , in the colon [32] and in the visceral adipose tissues [33] . In humans, the Y1 receptor is expressed in the colonic epithelium and mucosal nerve, in the heart, adrenal gland, kidney as well as the placenta [34] . In the human central nervous system, Y1 receptor mRNA was moderately expressed in the caudate nucleus, amygdaloid nuclei, putamen and arcuate nucleus (ARC) and the nucleus accumben [35] . As in human and the rat brain, discrepancy once exists regarding the existence and distribution of Y1 receptors in the telencephalon, in particular the striatum and cerebral cortex. Unlike earlier findings, the binding sites and mRNA of Y1 receptors are expressed abundantly in the human frontal cortex and, suggest that the human brain contains a mixture of Y1 and Y2 receptor subtypes [36] . There is also an important concern in terms of large and preferential inactivation of human Y1 sites post mortem [37] . It appears that Y1 receptors exist as a low affinity agonist conformation in postmortem samples of frontal cortex though considerable Y1 receptors in human cortex were detected [38] . The reason could be that the titers of Y1 receptor across brain areas depend to a varying degree on the post mortem interval prior to tissue homogenization or freezing [38] . The binding sites of Y1 receptor were sensitive to post-mortem delay whereas Y1 mRNA expression levels were not found to vary significantly within the post-mortem interval range examined in another study [37] . Thus, the Y1 sites in any tissue are much more prone to be inactivated by a variety of agents than that of Y2 receptors. Previous studies have shown that the Y1 receptor is involved in the regulation of hyperphagia, vasoconstriction of vascular smooth muscles, proliferation of neuronal precursors, as well as potentiating noradrenaline-evoked vasoconstriction post-junctional and decreasing ethanol tolerance [39, 40] . Furthermore, the hY1 receptor is highly expressed in human primary breast cancer and Ewing's sarcoma, suggesting that this receptor represents an important diagnostic and therapeutic target for these types of cancer [41, 42] . The most prominent and significant effects of the Y1 receptor is the regulation of energy homeostasis and the induction of food intake; these effects often require involvement of the Y5 receptor [43] . However, the knockout of either Y1 or Y5 receptors can induce late onset obesity, while Y5 receptor knockout also induces hyperphagia; this suggests that both Y1 and Y5 act in combination in the mediation of food intake.
Neuropeptide Y receptor Y2
The hY2 receptor consists of 381 amino acids and its preferred agonists are NPY and PYY. This receptor couples to NPY and PYY with high affinity, although its affinity for PP is relatively lower [4] . The hY2 receptor is mainly localized presynaptically and is predominantly expressed in central neuronal tissue, such as the brain, hippocampus, thalamus, hypothalamus and some parts of the peripheral nervous system (Table 1) . Studies have also reported the detection of hY2 in blood vessels, spleen, liver, gastrointestinal tract, kidney cortical slices and white as well as brown adipocyte tissue. The Y2 receptor is abundantly distributed in rodent and lagomorph kidney cortex and also detected in dog kidney [44] . In presynaptic neurons, hY2 is abundantly distributed and acts as a regulator in the release of neurotransmitters [3, 45] .The hY2 receptors also share over 92% sequence similarity with that of its orthologues such as mouse, rat, pig, guinea pig, and cow. Though been localized close to the Y1 and Y5 gene cluster on chromosome 4q31-32, the Y2 receptor turns out to be quite different from the Y1 receptor which shows only approximately 30% total amino acid sequence similarity with that of Y1 receptor [46, 47] .
Pharmacologically, the most important feature of the Y2 receptor is its role in the regulation of feeding, circadian ingestion, energy homeostasis, colonic transit and bone formation (Table 1) [48] . In central presynaptic neurons, the overexpression of Y2 receptors prevents the release of neurotransmitters [49] such as NPY and glutamate, suggesting that Y2 receptor act as a potential therapeutic target for epilepsy [50] . In addition, Y2 receptors also exert anorexigenic effects in humans since elevating the postprandial secretion of the Y2 receptor agonist, PYY , may act via Y2 receptor in the arcuate nucleus to prevent feeding through a gut-hypothalamic signaling system [51] . In overweight and obese humans, the expression of PYY (3-36) is additive and co-administration of Y2 receptor agonists and GLP-1 receptor agonists may be a useful treatment strategy for obesity [52] . Meanwhile, the Y2 receptor is also related to fear conditioning and fear extinction [53] , angiogenesis and restoration of ischemic skeletal muscles [54] , as well as ethanol-induced behavioral sensitization [55] . In central nervous system tumors, such as neuroblastoma and glioblastoma, the Y2 receptor is upregulated and acts as an inducer for tumor growth and vascularization [56] [57] [58] . In metabolic disorders, Y2 receptors are related to the promotion of adipocyte proliferation and differentiation, as well as the regeneration of adipose tissue capillaries, all of which could result in abdominal obesity and metabolic syndrome. Under cold or aggressive conditions, the production of NPY from the abdominal fat sympathetic nerves is increased and the Y2 receptors are upregulated in a glucocorticoid-dependent manner. This response leads to the accumulation of abdominal fat [59] . Peripheral-specific Y2 receptor knockdown experiments revealed a protective effect in mice against high-fat dietinduced obesity. Research aiming to investigate the relationship between the peripheral Y2 receptors and high-fat diet-induced obesity further showed that the individual knockdown of peripheral Y2 receptors can prevent diet-induced obesity. Interestingly, the effects of Y2 
Neuropeptide Y receptor Y4
The Y4 receptor was first cloned by homology cloning techniques [60] . This is the only subtype of the family which shows preferential affinity to PP, but can also be activated by PYY and NPY to some extent. In humans, the gene encoding the Y4 receptor is located in chromosome 10q11.2 and shows low levels of conservation with the other receptors. Y4 shares the least sequence identity (less than 86%) with that of its orthologues when compared to other Y receptor subtypes. The Y4 receptor is composed of 375 amino acids and is thus far found in the gastrointestinal tract [61, 62] , central nervous system such as the hippocampus and hypothalamus, pancreas, prostate and in human epidermis [60, [62] [63] [64] [65] .
Studies have shown that the Y4 receptor is involved in the regulation of feeding [66, 67] , circadian ingestion and energy homeostasis [68] and colonic muscle contraction [69] . The human Y4 receptor also plays a critical role in the regulation of food intake and reproductive functions [70] . Peripherally, the Y4 receptor can be activated by circulating PP and NPY, thus regulating energy homeostasis and emotional behavior in combination with the Y2 receptor [66, 71] . In the postrema region, this receptor is activated by PP and transmits anorexigenic signals from the peripheral circulation to the hypothalamus by regulating the vago-vagal reflex arc [66, 72] . In the arcuate of the hypothalamus, the Y4 receptors directly regulate the pancreatic polypeptide-mediated reduction of food intake by activating anorexigenic α-Melanocyte-stimulating hormone (α-MSH) signaling. Specific-knockout of the hypothalamus Y4 receptor conditionally eliminates polypeptide-mediated ARC c-Fos activation and prevents the PP-induced increase in proopiomelanocortin (POMC) mRNA expression. Collectively, these findings suggest that the Y4 receptor is a potential therapeutic target for the prevention of obesity [66] .
Neuropeptide Y receptor Y5
Research was carried out to test the existence of an additional Y receptor subtype, which was pharmacologically similar to the Y1 receptor, but had the ability to regulate NPY-induced feeding independently of the Y1 receptors. Eventually, the Y5 receptor was isolated and cloned from rat hypothalamic cDNA [34, 73, 74] . The Y5 receptor encoding gene is located on human chromosome 4(4q31) and overlaps with Y1 although Y5 is transcribed in the opposite direction. Pharmacologically, the Y5 receptor shows equal affinities to hNPY, hPYY and hPP. Structurally, the hY5 receptor mainly exists in two forms with similar pharmacological characteristics [75] : a long isoform consisting of 455 amino acids, and a shorter (splice variant) form consisting of 445 amino acids. When compared to other members of the Y receptor family, the third intracellular loop (ICL3) of the Y5 receptors, which consists of 140 amino acids, is much larger, while the C-terminus is much shorter. The Y5 receptor is well conserved, shares more than 85% sequence similarity with its orthologues, and is predominantly expressed in the central nervous system, including the thalamus, temporal cortex, hypothalamus and amygdala [76] . One of the alternative promoters and 5' exons of the Y1 gene is located within the coding sequence of the Y5 gene, suggesting the potential existence of partially coordinated transcriptional regulation between these two genes. Structurally, the genes encoding Y1 and Y5 receptors share a common promoter region, but are are transcribed in opposite directions, on human chromosome 4q31-q32 [77] . The similarity of these two Y receptor genes suggest that they arise from the same gene duplication event. Reverse transcription of the same gene sequence indicates that either one transcriptional activation of the two genes will exert influence on the expression levels of the other. In agreement with this, recent studies showed that the Y5 receptor can regulate energy homeostasis [43] , anticonvulsant effects [78] and anxiety [79] , and that these effects occur in combination in with the Y1 receptors. Since it is known that the Y1 and Y5 receptors are both involved in modulating food intake and energy homeostasis [80, 81] , the coordinated expression of their genes may be critical in regulating NPY activity [77] . The Y5 receptors were detected in a brain region related to memory processing and emotion regulation, indicating their potential involvement in mood control [74] . In a manner similar to the Y1 receptors, the Y5 receptor promotes cell growth in a human breast cancer cell line via an extracellular signal-regulated kinase pathway and by inhibiting the production of cAMP [82] . In situ hybridization and immunohistochemical staining has also shown that Y5 mRNA is apparently upregulated in areas of the central nervous system which are thought to regulate the action of food intake and feeding, thus supporting a role for the Y5 receptors in feeding and food intake [74, 83] .
The role of NPY receptors in metabolic diseases
Previous studies have demonstrated that the NPY family plays important roles in various physiological functions by binding to different types of NPY receptors. Activation or inhibition of NPY receptors could change the levels of some neurotransmitters which may, in turn, cause alterations in some physiological processes. Gene knockout studies have revealed various roles for the NPY receptors. For example, a series of investigations has reported that the NPY receptor may play a significant role in several diseases, particularly in terms of metabolism diseases such as diabetes, obesity, hypertension, and dyslipidemia. In this article, we summarize the potential role of NPY receptors in metabolic syndrome.
The relationship between NPY receptors and dyslipidemia
The elevation of hepatic very-low-density lipoprotein (VLDL)-triglyceride (TG) secretion leads to the occurrence of atherosclerotic dyslipidemia, which is closely related to diabetes, obesity and metabolic syndrome [84, 85] . A previous study reported that increased NPY in the neural circuits can result in dyslipidemia, independent of an increased total energy increment and visceral adipose accumulation. In paraventricular nucleus, long-term over-expression of NPY contributes to the establishment of adipose tissue insulin resistance partly through Y5 receptor [86] . A single injection of NPY into the third lateral ventricle can directly increase VLDL-TG secretion by one-fold in the liver of lean and fasted rats, a mechanism mediated predominantly by the central nervous system Y1 receptor [87, 88] . Studies conducted by Bruinstroop reported that the hypothalamic arcuate nucleus, along with hepatic sympathetic innervation, are essential factors in maintaining the secretion of VLDL-TG during fasting. In addition, the stimulatory effect of VLDL-TG secretion, caused by the intracerebroventricular injection of NPY, requires the involvement of hepatic sympathetic innervation [89] . The increased secretion of hepatic VLDL-TG resulting from intracerebroventricular NPY injection is independent of lipolysis, suggesting a liver-selective effect upon lipid metabolism. Collectively, these findings indicate that the sympathetic nervous system is essential to the stimulatory effect of increased NPY in fasted rat in maintaining hepatic VLDL-TG secretion [89] . Consist with this investigation, other studies [87] [88] [89] have shown that central nervous system NPY stimulates hepatic VLDL-TG secretion independent of changes in plasma free fatty acid levels. In the central nervous system, increased levels of NPY promotes the effect of sympathetic intervention in the liver, thus regulating key regulatory proteins to coordinate a multi-stage response and promote liver phospholipid remodeling and VLDL maturation, finally resulting in the increased secretion of hepatic VLDL [90] . This effect is mediated by the Y1 receptor and the sympathetic pathway.
The process of adipose accumulation consists of the proliferation and differentiation of adipocyte precursor cells, which are specialized in the accumulation of lipid. The differentiation of adipocytes is regulated by the coordinated expression of various transcription factors, of which peroxisome proliferator-activated receptor 2 (PPAR-2γ) is the most common type [91] . Numerous investigations have shown that NPY promotes and modulates the formation of adipose tissue. Previous studies have demonstrated that the increased local expression of NPY in visceral adipose tissue can promote the proliferation of pre-adipocytes and induce the accumulation of adipose tissue via Y1 receptor activation [33] . However, a study conducted by Kuo et al. reported that these processes were mediated via the Y2 receptor [59] . A more recent study reported that in adipocyte precursor cells, the exogenous dipeptidyl peptidase-
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IV (DPP-IV) inhibitor, vildagliptin, could prevent the formation of adipose and lipid accumulation stimulated by DPP-IV. The immunoneutralization of NPY, or inhibition of the Y2 receptor, can prevent this process, suggesting that DPPIV could promote the formation of adipose tissue by the cleavage of NPY and activation of the Y2 and Y5 receptors [92] . The Y5 receptor agonist-induced accumulation of lipid can be inhibited by protein kinase C (PKC) and PLC inhibitors. In addition, activation of the Y2 receptor can stimulate lipid accumulation via the protein kinase A, mitogen-activated protein kinases (MAPK) and phosphoinositide 3-kinase (PI3K) signaling pathways [92] . The DPPIV inhibitor, vildagliptin, suppressed the expression of PPAR-γ and the accumulation of lipid, with no effect upon lipolysis, indicating that this process has no effect on the storage of triglycerides inside the lipid droplets of adipose tissue. These results showed that the combined regulation of DPP-IV and NPY upon lipid metabolism can attenuate the deposition of adipose tissue [93] . Collectively, this data support the fact that NPY neurons, and the Y1 receptor, are increasingly regarded to have an important role in the modulation of lipid metabolism in the liver and exert potent roles in metabolic disorders.
The relationship between NPY receptors and obesity
Obesity, as a major risk factor for type 2 diabetes mellitus, heart disease, obstructive sleep apnea, and certain types of tumors and osteoarthritis, has become a worldwide epidemic as a result of social changes and improvements in living standards. These diseases are caused by long-term energy metabolism disequilibrium, together with an imbalance between energy intake and energy expenditure. Studies have revealed that NPY is a major regulator in balancing energy metabolism [26, 94, 95] and resists excessive loss of fat by lipolysis in calorie-restricted mice indicating a trait potential for the life-extending effect of calorie restriction [95] . The NPY receptors, as is reported, can regulate energy balance and body weight in a cooperative manner. For instance, in mice featuring either single or multiple Y receptor deletion (including Y1, Y2, and Y4), the long-term overexpression of hypothalamic NPY can result in a significant increase in food intake, fat accumulation, insulin levels and body weight. However, the combined deletions of Y1, Y2 or Y4 receptors can also prevent NPY-induced hyperinsulinemia [92] .
The Y2 receptor encoding gene is abundantly expressed in the central nervous system, especially in the hypothalamus, which is recognized as a crucial regulator of appetite. Knockout of the Y2 receptor can lead to increased weight gain and accumulation of adipose tissue. The ligand for Y2 receptor, PYY, is released in a postprandial from L cells in the distal part of the intestine in proportion to the amount of ingested food [96] . Peripherally, the administration of PYY can reduce the amount of ingested food and thus, the extent of weight gain. However, in Y2 receptor knockout mice, this effect does not exist [51] . The postprandial level of circulating PYY is relatively higher in obese subjects than that in lean subjects [97] , which indicates that PYY gene variants can change the expression of circulating PYY. A number of research studies have investigated the relationship between variations in the gene encoding for the Y2 receptor and obesity. In fact, in a population-based study, which enrolled 5, 965 subjects, the PYY common allele Arg72 variant was shown to be related to type 2 diabetes and excessive weight gain [98] . In Pima Indians (a population genetically affected by obesity), severe obesity was found to be linked to mutations in both the Y2 receptors and the PYY gene [99] . These data indicated that the PYY-Y2 receptor signaling pathway may be involved in the regulation of body weight via a gender-specific mechanism. Consistent with this result, another study, which enrolled 1, 800 North American, 1, 030 Polish and 240 Scandinavian participants, showed that genetic mutations in the 5' region of Y2 receptors were closely related to obesity [100] . However, in early onset obesity, PYY and Y2 receptors genetic variants have no relationship with obesity. Body mass index and waist-to-hip ratio were significantly lower in 421 white homozygous-carrying males with Y2 receptors Ile195 (rs1047214) [101] , whereas directly opposite results were obtained for 479 homozygouscarrying Swedish males [102] . A further study enrolled 5, 971 white Danish subjects and reported that the common variants rs6857530, rs12649641, and rs2342676, located in the 5' region of Y2 receptors were related to obesity [103] . However, since existing data have arisen from different regions and ethnic groups, further studies are required which should feature larger sample sizes and be based upon a multi-center approach.
Over recent years, the Y1 and Y5 receptors have attracted increasing pharmacological attention as potent anti-obesity targets. Numerous NPY knockout, and NPY receptor deficient models, have demonstrated that these two receptor subtypes play a pivotal role in the regulation of body weight, food intake and fat accumulation. However, since there are various neural signaling pathways involved in maintaining the homeostasis of food intake and energy balance, few antagonists have been identified and tested in clinical trials. These factors mean that the identification of ligands with higher selectivity and affinity is very important for the future. The Y1 signaling pathway is essential to the process of insulin resistance and obesity in the hematopoietic system of diet-induced obese mice; moreover, this effect was specific to the Y1 receptor and did not involve the Y2 receptor [104] . The elevation of NPY by chronic intracerebroventricular NPY injection was also shown to induce obese-like secretion changes of hormone and metabolism parameters in normal rats [28] . Centrally, the chronical activation of NPY Y1, Y2 or Y5 receptors in mice can modulate the balance of energy metabolism and food intake. Over a duration of 6 days, the administration of NPY, Y1 or Y5 agonists resulted in significant increases of body weight, adiposity, and respiratory quotient in C57Bl/6 mice. In contrast, selective activation of the Y2 receptor can cause transient reductions in weight [105] .
The mRNAs for Y1, Y2, and Y5 receptor are detectable in human adipose tissue, indicating that NPY plays a significant role in this region. A clinical study [106] investigated the expression of Y1 receptor mRNA in visceral adipose of obese subjects and showed that circulating Y1 receptor mRNA levels were much higher than that in participants of normal weight; however this phenomenon was not evident in subcutaneous adipose. In visceral adipose tissue, Y1 receptor mRNA level was positively correlated with body mass index, waist and hip circumferences as well as body weight. These data suggest that elevated NPY circulating levels are related to obesity in visceral adipose tissue. These results are consistent with previous findings that the inhibition of Y1 receptor expression, or Y1 receptors deficiency, can reduce body weight in mice. However, the molecular mechanisms and NPY-Y1 receptor signaling pathway involved in this phenomenon remain unclear. In rats, NPY regulates the proliferation of pre-adipocytes by extracellular regulated protein kinases signaling [33] , and specific Y1 receptor antagonists can inhibit lipolysis [107] .
Collectively, these data indicate that the expression of Y1 receptor in visceral adipose tissue is associated with the development of obesity and the formation of adipose tissue. The molecular factors underlying this mechanism now needs to be investigated in future research studies. Moreover, since the genes encoding Y receptors vary across different ethnic populations, and because genetic variants of Y receptors could exert different functions and may play roles in different physiological processes, it is necessary to conduct further research studies to elucidate the specific effects of different Y receptors in different regions.
The relationship between NPY receptors and diabetes
Type 2 diabetes, in around 90% of cases is characterized by insulin resistance and defective islet beta cell function. Pre-diabetes is characterized by hyperinsulinemia, impaired glucose tolerance, as well as insulin resistance which is associated with the dysfunctional islet beta cells [108] . Previous studies demonstrated that in diabetes models, NPY exerts a profound role in the regulation of blood glucose homeostasis [26] . Insulin acts on NPY neurons and modulates the balance of energy regulation and the dysfunction of which may result in the development of metabolic diseases. Meanwhile, by changing the pain response and transduction of the orofacial sensory pathways, diabetes mellitus influences the trigeminal nerve function and affects inflammatory response via NPY and vascular endothelial growth factor since an increased percentage of NPY + neurons was observed both in type 1 and 2 diabetes [109] .
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Pituitary adenylate cyclase activating polypeptide (PACAP), sensory fiber substance P (SP) and sympathetic neuropeptide Y (NPY) are co-transmitters in the process of neuronal signal transmission and both PACAP and SP have been shown to have an impact upon the insulin sensitivity of adipocytes [110] . With regards to NPY, studies have mainly focused upon the influence upon glucose metabolism in adipocytes. Notably, the activation of NPY receptors leads to the inhibition of adenylate cyclase in conjunction with a reduction of cyclic adenosine monophosphate levels or binding to other signal systems, such as calcium influx, which is modulated via the Y1 receptors in a preferential manner. Moreover, NPY acts as a potent therapeutic target for obesity and type 2 diabetes in that Y2 receptor inhibitors could prevent the progress of obesity and impair glucose tolerance; moreover the increased expression of NPY caused by chronic stress can cause hyperinsulinemia [59] . NPY also plays a significant role in the regulation of insulin sensitivity in 3T3-L1 adipocytes [111] . By transporting impaired GLUT4, NPY prohibits the uptake of glucose stimulated by insulin via the AKT signaling pathway. On the surface of 3T3-L1 adipocytes, the increase of GLUT4 was ameliorated and the phosphorylation of AKT mediated by insulin was prevented by NPY and this could result in the inhibition of glucose uptake. NPY impairs the phosphorylation of AKT through the Y1 receptor signaling pathway in a GLUT4-dependent manner, which thus leads to the inhibition of glucose uptake induced by insulin secretion [112] . The administration of an NPY Y1 receptor agonist reduced the translocation of GLUT4 induced by insulin secretion, suggesting a critical role of the Y1 receptor in the translocation of GLUT4. However, since the phosphorylation of AKT is independent of the insulin signaling pathway and glucose uptake, NPY could not completely inhibit the translocation of GLUT4 [113] ; this study provided evidence that NPY impairs the insulin sensitivity of adipocytes and further suggested that the Y1 receptors could be a potential therapeutic target for type 2 diabetes [111] . These findings concurred with those arising from experiments using transgenic mice. For example, the secretion of insulin was elevated in the pancreatic islets of mice in which NPY had been deleted. NPY and the Y1 receptors are now recognized to play a physiological role in the progression of diabetes [114] . A reduction in pancreatic NPY leads to increased levels of insulin secretion from the islets to compensate for obesity-mediated insulin resistance, whereas endogenous NPY in the islet cells stimulate the secretion of pancreatic insulin. Taken together, these data prove that NPY can promote sensitivity to insulin in adipocytes, which therefore act as potential therapeutic targets for type 2 diabetes together with the Y1 receptors.
It was found that circulating NPY levels are significantly elevated in both diabetic rats and patients [115] . NPY has a critical impact upon the regulating secretory function of pancreatic α and β cells [116] as well as β cell differentiation both in mice and humans [117] . Under different circumstances，NPY can exert opposite functions upon the secretion of glucagon and insulin. Moreover, NPY Y1 receptors are expressed on the surface of pancreatic islet cells and NPY autoantibody could be used as diagnostic indicator of Type 1 diabetes [118] . Mutation of NPY receptor type 2 may lead to type 2 diabetes [119] . NPY-induced transient ERK1/2 phosphorylation can also promote the proliferation and replication of islet beta cells via the activation of extracellular signal-regulated kinase [116] . During the development of pancreas，NPY expression is restricted from the progenitor populations and marks functionally immature β cells in fetal and neonatal mice and humans [120] . NPYpositive cells were detectable in the central and periphery regions of islet cells in diabetic rats, although in normal rats, NPY-positive cells were only found in the peripheral regions of islet cells. Among all pancreatic cell types, NPY is predominantly expressed in PP cells under normal conditions. However, in the presence of a high-fat diet, or under diabetic conditions (both type 1 and type 2), the localization of NPY expression in pancreatic cell types changes; NPY expression in PP cells is relatively lower while the number of NPY positive cells in the islets increases markedly [121] . The level of NPY expression is epigenetically downregulated during the maturation of βcells. In neonatal mouse, NPY expressingβcells are more replicative, and the knockdown of NPY gene could reduce replication ofβcells and enhances insulin secretion in response to high glucose. Those findings indicating that the expression Cellular Physiology and Biochemistry
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of NPY may promote the replication of neonatal βcells and contributes to impaired glucose responsiveness. In diabetic mice and those fed with high-fat diet, the expression of NPY expression reemerges which may explain the impairedβcell maturity in diabetes. Taken together, NPY could regulateβcell differentiation and have potential applications on β cell supplementation for diabetes therapy [120] . NPY is widely expressed in the cardiovascular system [122] and is also known to play an essential role in the modulation and pathological process of diabetic cardiomyopathy besides food intake, body weight, energy homeostasis, peripheral vascular tone and various other conditions [123] . In the myocardium of the diabetic rat, the expression of NPY was shown to be different than other tissues and its receptors were up-regulated [124] . In the cardiovascular system, NPY is co-expressed and co-exists predominantly in the coronary arteries, endothelium [122] and cardiomyocytes innervated by sympathetic nerves together with other classic neurotransmitters such as sympathetic noradrenaline. NPY receptors, particularly the Y1 and Y2 receptors, have been demonstrated to play a fundamental role in the pathogenesis of myocardial hypertrophy in the rat [124] . Indeed, NPY Y1 receptor expression was elevated in rat myocardium leading to hypertrophy of the cardiac myocytes via reduced degradation and the increased synthesis of protein via PI3K/p70 signaling pathways [125] . Research has also revealed that activation of the Y2 receptor stimulates the process of angiogenesis, both in vitro and in vivo. Some researchers believe that the levels of leptin, and leptin resistance, changes in diabetic conditions, which in turn, affects the expression of NPY and its receptor distribution in the hypothalamus and peripheral autonomic nervous system. However, the exact mechanisms and interactions between leptin and NPY still remain unclear. An earlier study [126] investigated diabetic and non-diabetic patients and showed that the expression of neuropeptide in the serum and myocardium differed. Plasma NPY levels were significantly elevated in patients with type 2 diabetes when compared to non-diabetic patients, whereas in atrial tissue, NPY mRNA levels were lower in diabetic patients. In diabetic patients, myocardial Y2 and Y5 receptors were upregulated, while the apoptosis and angiogenesis hormone, leptin was downregulated. Furthermore, the Y1 receptors appeared to be preferentially expressed in the nuclei of cardiomyocytes and vascular smooth muscle cells. The same phenomenon was also shown to exist in animal models of chronic hyperglycemia [124] and may occur because of the counter regulation response to reduced levels of NPY. However, whether these alterations in NPY and its receptors are associated with the initial etiology of disease in the myocardium requires further investigation.
The relationship between NPY receptors and hypertension
Over recent years, some researchers have begun to investigate the molecular and cellular mechanisms underlying human NPY-mediated gender-difference in the regulation of blood pressure. It was reported that long-term administration of NPY in the subcutaneous infusion could induce cardiac dysfunction and cardiac hypertrophy of which may be mediated by the Ca
2+

/CaM
-dependent CaN pathway and p38 mitogen-activated protein kinase (MAPK) signal pathway in rats [127] . The proliferation and migration of vascular smooth muscle cells plays a vital role in pathophysiological remodeling of arteries during hypertension in pregnancy. NPY could promote the proliferation and migration of vascular smooth muscle cells via Y1, Y5 receptors and in vascular tissues in vivo via Y5 receptor [128] . Human hypertension is heritable [129] , and exhibits pleiotropic determination with autonomic activity. Some previous studies have investigated correlations between catecholamine secretion and genetic variation in the adrenergic pathway, which controls catecholamine synthesis, and revealed new pathophysiological correlations between important adrenergic loci, blood pressure and catecholamine secretion [130] . NPY can regulate blood pressure, and the activation of adrenaline, by coupling to the NPY Y1 receptor. In transgenic rodents, overexpression of the NPY gene attenuated the elevation of blood pressure after central Nitric Oxide Synthase (NOS) inhibition administration; the injection of a selective Y1 receptor antagonist, BIBP3226, was shown to reverse this phenomenon centrally [131] . In mice, the specific deletion of the gene encoding NPY Y1 receptor results in changes in adrenergic activity, as well as enhanced biosynthesis and secretion of catecholamine [132] . Peripherally, NPY activates the NPY Y1 receptor receptor and modulates vasoconstrictor or vasopressor responses [133] , while centrally, these effects may be the total opposite, and are usually antihypertensive [131] .
NPY is highly expressed in the cardiovascular neural control center and co-localized with other excitatory neurotransmitters, such as norepinephrine or glutamate; research has shown that NPY is able to prevent the expression of these neurotransmitters [49, 134, 135] . These observations indicate that NPY modulates physiological effects by acting as a buffering neurotransmitter in the central nervous system. Consistent with this theory, a study conducted by Michalkiewicz et al. [136] found that NPY-enhanced signaling could alleviate chronic hypertension mediated by nitric oxide (NO) deficiency. The central Y1 receptor subtype could modulate the hypertensive effect caused by increased NPY signaling and may act as a potent antihypertensive target. Another study demonstrated that NPY is an effective vascular contractor and is co-transmitted with sympathetic norepinephrine. These effects were mediated mainly by the increasing activity and expression of Rho kinase in the vascular wall of the mesenteric artery, and by reducing the excessive production of NO in the mesenteric vascular wall, thus leading to the contraction of mesenteric arteries and portal hypertension [137] .
The nucleus of the solitary tract, located in the dorsal medulla of the brainstem, is the main control center for cardiovascular and other autonomic functions in the central nervous system. This is a medullary relay nucleus which expresses Y1 and Y2 receptors and delivers cardiovascular and respiratory signals [138] . NPY is expressed abundantly in the brainstem (the nucleus of solitary tract, the area postrema, and the dorsomotor nucleus of the vagus), and peripheral sympathetic nerves play critical roles in the regulation of blood pressure. A microinjection of NPY into the nucleus of the solitary tract can induce a dose-dependent reduction in both blood pressure and heart rate, while the NOS inhibitor, via NPY receptormediated downstream signaling, can cause the enhancement of systemic arterial pressure and renal sympathetic nerve activity [139] . In the nucleus of the solitary tract, NPY regulates blood pressure and exerts a depressor effect by activating two signaling pathways: the Y1 receptor-PKC-ERK-ribosomal protein S6 kinase (RSK)-eNOS pathway and the Ca
2+
-eNOS signaling system [131] .
Hypertension in pregnancy is a disorder involved with the pathophysiological remodeling of the vasculature. Neuropeptide Y has been proven to be a risk factor for the cardiovascular system and was found in increased levels in hypertensive pregnant patients [140] . In pregnant hypertensive rats, circulating levels of NPY are also elevated, and this was reported to be associated with the proliferation and migration of vascular smooth muscle cells (VSMCs). In hypertensive pregnancies, the proliferation and migration of VSMCs changes via several signaling pathways, including MAPKs, Ca 2+ [141] and G-proteins [142] . By activation of the Y5 receptor, circulating NPY expression was increased and the proliferation of VSMCs was induced. Consequently, signal transducer and activator of transcription 3 (STAT3) and c-Fos signaling pathways were activated. These finding indicate that NPY predominantly exerts its effects upon VSMCs via the Y5 receptor in vivo. In vitro, however, NPY mainly acts on VSMCs via both Y1 and Y5 receptors. Postsynaptic Y1 receptors modulate vasoconstriction and hypertension effects by enhancing norepinephrine-mediated contraction and VSMC proliferation [143] . Since the molecular mechanism of hypertension during pregnancy is very complicated, further research studies are needed in order to clarify the opposing effects of Y receptors in different tissues, as well as the co-regulated functions and inter-reactions between Y receptors.
Conclusion
In humans, NPY has been shown to bind to at least five different receptors: Y1, Y2, Y4, Y5, and y6. However, only four of these (hY1, hY2, hY4 and hY5) are functional in humans. Of note, NPY has been confirmed to interact with some other types of receptors, both in vitro and in vivo, such as the sigma receptor. Over recent years, several new receptors have been discovered; these advances have occurred via the use of intracerebroventricular (ICV) and other technologies. However, the mechanisms and pathways mediating the various functions and processes carried out by NPY receptors in different organs and tissues still need to be clarified. It is possible that mechanisms other than coupling to G-proteins may be identified in future. Furthermore, the potential roles of NPY receptors in the process of the browning of white adipocyte tissue and metabolism disorders such as diabetes, obesity and hypertension also need to be elucidated; studies in this area may provide new insight into novel treatment options for these types of diseases. Further studies and efforts should therefore aim to discover high affinity and specific NPY receptors as potential therapeutic agents. In addition, the modification of NPY receptors for specific purposes should be given more research attention.
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